Extended Data Table 4 Adverse events that occurred in 10% or more of participants in either group of the as-treated population

From: The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  1. The treatment regimen included trastuzumab and chemotherapy in both groups.
Back to article page